Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Refractory Chronic ITP
NCT00102739Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of eltrombopag in immune thrombocytopenic purpura (ITP), sponsored by GSK. Started Feb 2005; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00102739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102739.